Bladder Cancer : Advances in Diagnosis and Clinical Care

4543. 29. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol. 2006;7:43-51. 30. Southwest Oncology Group. Gemcitabine after surgery in treating patients with newly diagnosed or recurrent bladder cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00445601 (accessed 4 December 2011). 31. van der Heijden AG, Moonen PM, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol. 2006;176:1349-1353. 32. Spectrum Pharmaceuticals, Inc. Efficacy and safety of multi-instillations of apaziquone in patients with non-muscle invasive bladder cancer. Available at: http://clinicaltrials.gov/ct2/show/ NCT01410565 (accessed 4 December 2011). 33. Spectrum Pharmaceuticals, Inc. Efficacy and safety study of apaziquone vs. placebo in patients with non-muscle invasive bladder cancer (NMIBC). Available at: http://clinicaltrials.gov/ ct2/show/NCT01469221 (accessed 4 December 2011). 34. Spectrum Pharmaceuticals, Inc. Phase 3 trial of single-dose intravesical EOquin® as a surgical adjuvant for noninvasive bladder cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00598806 (accessed 4 December 2011). 35. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem.